CPRX

Catalyst Pharmaceuticals' stock price has been influenced by strong financial results, a share repurchase program, and generic competition for FYCOMPA. Recently, Angelini Pharma S.p.A. announced a definitive agreement to acquire Catalyst Pharmaceuticals for approximately $4.1 billion, or $31.50 per share in cash, expected to close in the third quarter of 2026. Catalyst Pharmaceuticals also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs Ltd., resolving all pending FIRDAPSE patent disputes and pushing any potential generic competition to January 2035.